dalfopristin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, streptogramins, protein-synthesis inhibitors, pristinamycin derivatives 778 112362-50-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dalfopristin mesilate
  • dalfopristin
  • dalfopristin mesylate
  • RP-54476
component of RP-59500
  • Molecular weight: 690.85
  • Formula: C34H50N4O9S
  • CLOGP: 1.35
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 2
  • TPSA: 176.42
  • ALOGS: -3.96
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 15.20 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.39 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.82 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.74 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.03 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Sept. 21, 1999 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01FG02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Streptogramins
FDA CS M0022748 Streptogramins
FDA EPC N0000175502 Streptogramin Antibacterial
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:48001 protein synthesis inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vancomycin resistant enterococcus indication 113727004
Streptococcus pyogenes infection indication 302809008
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Pyrexia of unknown origin off-label use 7520000
Hyperbilirubinemia contraindication 14783006 DOID:2741
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.67 acidic
pKa2 4.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4021183 VUID
N0000179689 NUI
D00853 KEGG_DRUG
229369 RXNORM
4021183 VANDF
C0756085 UMLSCUI
CHEBI:4309 CHEBI
DOL PDB_CHEM_ID
CHEMBL1200937 ChEMBL_ID
DB01764 DRUGBANK_ID
C113826 MESH_SUPPLEMENTAL_RECORD_UI
10797 IUPHAR_LIGAND_ID
6581 INN_ID
R9M4FJE48E UNII
6323289 PUBCHEM_CID
8300 MMSL
d04456 MMSL
007888 NDDF
116111008 SNOMEDCT_US
387016001 SNOMEDCT_US
427378005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Synercid HUMAN PRESCRIPTION DRUG LABEL 2 61570-260 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 26 sections
Synercid HUMAN PRESCRIPTION DRUG LABEL 2 61570-260 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 26 sections